Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic
The National Multiple Sclerosis Society and the Centers For Disease Control together provide thorough, up-to-the-minute information for RRMS sufferers using Lemtrada during the COVID-19 pandemic
Friday, April 10, 2020 - Here's the latest information for those suffering from relapse-remitting multiple sclerosis and are using or contemplating using Lemtrada to mitigate their RRMS symptoms. Lemtrada is considered an immunosuppressant, and the most extreme disease-modifying therapy (DMT) and should only be administered after a risk assessment questionnaire has been completed and signed by both doctor and patient and in the presence of qualified emergency medical care personnel and medical emergency equipment. The National Multiple Sclerosis Society (NMS) gives its guidance to patients as to what to do and expect during the global COVID-19 pandemic.
The first objective of the NMS guidance is to clear up the confusion that may exist in the minds of RRMS patients. Any patient currently on DMT or considering starting should consult with their physician before making a decision. The Center for Disease Control should be considered the definitive source for information regarding the status of the pandemic. Lemtrada stroke lawsuit represented by top national attorneys offering a free no obligation consultation before filing a claim and work on contingency.
Patients with RRMS and taking DMT are in the highest risk group for succumbing to the virus, however, there is no reason to stop treatments until an MS healthcare provider has been consulted. DMTs in and of themselves, including Lemtrada, carry the risk of causing sudden death, a factor that should be taken into account before starting treatments. The NMS has looked to the Consortium of Multiple Sclerosis Centers (CMSC) and all other members of the MS Coalition in formulating their guidance. Lemtrada is considered a high-risk cell depleting therapy and others include Mavenclad, Ocrevus, and Rituxan according to NMS. Lemtrada (alemtuzumab )"depletes certain types of immune system cells known as lymphocytes and is considered an immunosuppressant and therefore may increase your risk of infections, including COVID-19."
The NMS feels that individuals should not necessarily stop their DMT due to an added risk of death from COVID-19. The NMS explains: "Based upon what is known right now, the National MS Society does not believe stopping your DMT is necessary. Stopping your DMT may place you at greater risk for new MS activity. We do recommend that you speak with your MS provider for advice about your specific situation and weigh the risks and benefits." The NMS also advises RRMS patients not to postpone a prescribed but pending DMT treatment due to the COVID-19 crisis. Other factors must be taken into consideration such as one's age and medical history and a physician should be consulted. "You should start your DMT. Some DMTs may increase your risk of infections, including COVID-19. This must be weighed against other factors including your MS activity, your age, other medical conditions and other potential factors that could impact your DMT, " according to the NMS. The NMS also recommends that one should not necessarily switch DMT to one that carries less chance of contracting COVID-19 as switching to a less effective drug could expose RRMS patients to even greater risk.
More Recent Lemtrada Stroke Lawsuit News:
- Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
- The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
- RRMS Has Different Stages With Different Symptoms | 4/5/2021
- Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
- Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
- Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
- MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
- Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
- Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
- Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
- People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
- Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
- Lemtrada Patients Have May Have Safer Options | 12/8/2020
- Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
- Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
- Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
- Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
- Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
- Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
- Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
- Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
- Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
- Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
- Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
- RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
- New Information About COVID19 and Taking Lemtrada | 7/16/2020
- The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
- Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
- A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
- Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
- Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
- RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
- Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
- Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
- Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
- Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
- Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
- Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
- Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
- Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
- Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
- Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
- Lemtrada Fears May Be Overdone | 1/30/2020
- Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
- One Last Lemtrada Warning for 2019 | 1/2/2020
- RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
- Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
- Lemtrada Side Effect Awareness Requirements | 12/11/2019
- Lemtrada is serious medication for a serious condition | 11/21/2019
- More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
- RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
- Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
- Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
- Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
- Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
- RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
- Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
- Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
- Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
- Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
- Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
- Lemtrada Patients Report Promising Results | 8/1/2019
- The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
- What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
- Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
- Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
- Treating Multiple Sclerosis From Many Angles | 6/21/2019
- Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
- A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
- A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
- Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
- The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
- Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
- The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
- The Pros and Cons of Lemtrada Therapy | 4/19/2019
- Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
- Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
- MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
- Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
- Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
- Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019
No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.